| 背景 | ICH5852 is a research-grade biosimilar of seniprutug, supplied as an unconjugated, non-therapeutic analogue of the originator antibody for research use only. It is a human IgG1/kappa molecule built around the same target the originator engages, the TRBV9 gene segment of the T-cell receptor beta chain, and is intended purely as a laboratory reagent rather than a clinical drug. Seniprutug is notable as a first-in-class depleting antibody: it binds T lymphocytes carrying a TRBV9-encoded receptor and eliminates them through Fc-mediated effector functions (antibody-dependent cellular cytotoxicity, antibody-dependent phagocytosis, and complement-dependent cytotoxicity). The originator was developed for HLA-B27-associated axial spondyloarthritis, where TRBV9-bearing CD8+ T-cell clones are implicated in the disease process. As a biosimilar reagent, ICH5852 supports characterisation of TRBV9 engagement, comparative binding studies, and effector-function assays. It is manufactured to research-grade low-endotoxin specifications (typically less than 1 EU/mg) and is available in bulk milligram-to-gram quantities to support in-vitro and functional workflows. It is not a clone-defined hybridoma antibody and is not intended for diagnostic or therapeutic use.
TRBV9 is a variable gene segment of the human T-cell receptor beta chain. When rearranged with diversity and joining segments, it contributes the V region of the TCR beta chain, forming part of the alpha-beta T-cell receptor that, together with the CD3 complex, recognises peptide antigens presented on MHC molecules. TRBV9-encoded receptors are expressed on a defined subset of T lymphocytes at the cell surface. Interest in TRBV9 stems from observations that CD8+ T-cell clones bearing a characteristic TRBV9-associated CDR3 motif are enriched in HLA-B27-positive individuals with ankylosing spondylitis, suggesting a role for these clones in the initiating immunopathology. Selectively targeting the TRBV9 segment allows depletion of this specific T-cell population while sparing the broader T-cell repertoire, which is the rationale underpinning the originator antibody. |
|---|
